Omega PF™ from Aplos Medical Marks a Significant Breakthrough in GERD Treatment

Saturday, November 04, 2023

Aplos Medical, previously known as CT Resources, is delighted to announce a significant achievement in the treatment of Gastroesophageal Reflux Disease (GERD). They have successfully implanted their innovative Omega PF™ device, marking a noteworthy milestone in GERD treatment.

For over eight decades, surgeons have grappled with the challenges of effectively addressing GERD while minimizing side effects. Traditional surgical approaches often resulted in esophageal restriction, effectively preventing reflux but unfortunately causing swallowing difficulties, or dysphagia.

The Omega PF™ device represents a groundbreaking shift in GERD treatment. It introduces a dual-modality approach, not only effectively controlling reflux but also ensuring a natural and unimpeded swallowing process for the patient. What makes this device unique is its simplicity and effectiveness, making it a promising choice for surgeons. The laparoscopic implant procedure is straightforward and can be easily replicated by qualified medical professionals.

After undergoing comprehensive clinical studies, the Omega PF™ device has the potential to transform GERD treatment. This innovation promises to benefit patients, surgeons, and healthcare providers by establishing a new standard of care in the field and ushering in a new era in GERD treatments. The Omega PF™ device's straightforward design aims to address common issues associated with existing GERD treatment methods.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO Summit - USAHealthcare CMO Summit - USAHealthcare CFO, Financial Strategy & Revenue Cycle SummitHealthcare CEO & Executive Strategy Summit